The Filing Desk

HUTCHMED (China) vs Mirum Pharmaceuticals

HUTCHMED (China) HCM · Mirum Pharmaceuticals MIRM · Pharmaceuticals

HUTCHMED (China) reported revenue of $548 million in fiscal 2025, about the same as Mirum Pharmaceuticals' $521 million in fiscal 2025. HUTCHMED (China)'s revenue fell 13.0% in its latest year, and Mirum Pharmaceuticals' grew 54.7%. HUTCHMED (China) had an operating margin of -7.1%, against -4.2% at Mirum Pharmaceuticals. Free cash flow was −$79 million at HUTCHMED (China) and $55 million at Mirum Pharmaceuticals.

Side by side

HUTCHMED (China)Mirum Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$548M$521M
Revenue growth−13.0%54.7%
Revenue growth a year, last 5 years19.2%—
Gross margin38.7%—
Operating margin−7.1%−4.2%
Net margin83.3%−4.5%
Free cash flow−$79M$55M
Free cash flow margin−14.4%10.5%
Return on capital—−7.1%
Net debt to EBITDA—−34.9x
Dividends and buybacks$0M$0M
Change in diluted share count0.0%5.6%
Last close$13.45$95.51
P/E at the last close——
Insider trades, last 12 months—bought $9.0 million, sold $43.1 million
Piotroski F-score4 of 95 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
HUTCHMED (China)Mirum Pharmaceuticals
Operating margin
Percent of revenue
HUTCHMED (China)Mirum Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
HUTCHMED (China)Mirum Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the HUTCHMED (China) and Mirum Pharmaceuticals pages.